CURE’S COMMITMENT TO INNOVATION
Not much has changed in how medications are delivered. Isn’t it time to take a new approach?
CURE’s pharmaceutical cannabinoid program targets opportunities that are not currently met by traditional pharmaceuticals. We leverage the synergism between cannabinoids and terepenoids in conjunction with CUREfilm™ to improve bioavailability of cannabinoid molecules. Our goal is to develop greater therapeutic efficacy in the evolving field of pharmaceutical cannabis.
Our technology can improve the efficacy and safety of new and existing drugs, match or improve pharmacokinetic drug profiles, and stabilize plasma levels over extended time periods, possibly reducing dose frequency and side effects.
Pharma companies can’t afford to partner with companies that are unresponsive to their needs. CURE has an uncompromising commitment to relationship management and partner satisfaction and has proven its ability to collaborate effectively through its growing portfolio and pipeline.
December 29, 2017
We’re all aware of the evolving law as it relates to medical cannabis (and cannabis in general). In the US, some… READ MORE
December 29, 2017
The pharmaceutical industry is rightly known for its rigorous clinical trial approach. In order to maximize commercial opportunities, pharma companies identify… READ MORE
November 7, 2017
CURE to Manufacture Therapix Proprietary Entourage Formulation (Dronabinol and PEA)-Based Product Using Proprietary CureFilm™ Technology OXNARD, Calif., Nov. 07, 2017 (GLOBE… READ MORE
August 10, 2017
OXNARD, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical(OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development… READ MORE
July 11, 2017
OXNARD, Calif. and TEL AVIV, Israel, July 11, 2017 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery… READ MORE